Document Detail


Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial.
MedLine Citation:
PMID:  19289640     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Chronic heart failure remains a major cause of mortality and morbidity. The role of antithrombotic therapy in patients with chronic heart failure has long been debated. The objective of this study was to determine the optimal antithrombotic agent for heart failure patients with reduced ejection fractions who are in sinus rhythm. METHODS AND RESULTS: This prospective, randomized clinical trial of open-label warfarin (target international normalized ratio of 2.5 to 3.0) and double-blind treatment with either aspirin (162 mg once daily) or clopidogrel (75 mg once daily) had a 30-month enrollment period and a minimum of 12 months of treatment. We enrolled 1587 men and women >/=18 years of age with symptomatic heart failure for at least 3 months who were in sinus rhythm and had left ventricular ejection fraction of </=35%. The primary outcome was the time to first occurrence of death, nonfatal myocardial infarction, or nonfatal stroke. For the primary composite end point, the hazard ratios were as follows: for warfarin versus aspirin, 0.98 (95% CI, 0.86 to 1.12; P=0.77); for clopidogrel versus aspirin, 1.08 (95% CI, 0.83 to 1.40; P=0.57); and for warfarin versus clopidogrel, 0.89 (95% CI, 0.68 to 1.16; P=0.39). Warfarin was associated with fewer nonfatal strokes than aspirin or clopidogrel. Hospitalization for worsening heart failure occurred in 116 (22.2%), 97 (18.5%), and 89 (16.5%) patients treated with aspirin, clopidogrel, and warfarin, respectively (P=0.02 for warfarin versus aspirin). CONCLUSIONS: The primary outcome measure and the mortality data do not support the primary hypotheses that warfarin is superior to aspirin and that clopidogrel is superior to aspirin.
Authors:
Barry M Massie; Joseph F Collins; Susan E Ammon; Paul W Armstrong; John G F Cleland; Michael Ezekowitz; Syed M Jafri; William F Krol; Christopher M O'Connor; Kevin A Schulman; Koon Teo; Stuart R Warren;
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2009-03-16
Journal Detail:
Title:  Circulation     Volume:  119     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2009 Mar 
Date Detail:
Created Date:  2009-03-31     Completed Date:  2009-04-24     Revised Date:  2009-11-17    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1616-24     Citation Subset:  AIM; IM    
Affiliation:
Department of Veterans Affairs, San Francisco, CA, USA.
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00007683
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Aspirin / administration & dosage
Chronic Disease
Death
Double-Blind Method
Female
Fibrinolytic Agents / administration & dosage*
Heart Failure / complications,  drug therapy*,  mortality
Humans
Male
Middle Aged
Myocardial Infarction
Stroke
Stroke Volume
Ticlopidine / administration & dosage,  analogs & derivatives
Warfarin / administration & dosage
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 50-78-2/Aspirin; 55142-85-3/Ticlopidine; 81-81-2/Warfarin; 90055-48-4/clopidogrel
Comments/Corrections
Comment In:
Circulation. 2009 Nov 17;120(20):e164   [PMID:  19917893 ]
Circulation. 2009 Mar 31;119(12):1559-61   [PMID:  19332479 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Molecular architecture of the human sinus node: insights into the function of the cardiac pacemaker.
Next Document:  Funny current downregulation and sinus node dysfunction associated with atrial tachyarrhythmia: a mo...